NCT05676697 is a Phase 1 clinical trial of Linperlisib in Autoimmune Hemolytic Anemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT05676697?

NCT05676697 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT05676697?

Interventions in NCT05676697: Linperlisib.

What condition does NCT05676697 study?

NCT05676697 studies Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment.

Is NCT05676697 still recruiting?

NCT05676697 is currently terminated. Last updated 11 February 2026.

Last reviewed 2026-02-11 · How we verify

NCT05676697

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Terminated Phase 1 Last updated 11 February 2026

What this trial tests

Phase 1 trial testing Linperlisib in Autoimmune Hemolytic Anemia in 4 participants. Terminated before completion.

Timeline

13 January 2023

Primary endpoint
31 January 2024

6 February 2024

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	13 January 2023
Primary completion	31 January 2024
Estimated completion	6 February 2024
Sites	2 locations across China

Drugs / interventions tested

Linperlisib — full drug profile →

Conditions studied

Autoimmune Hemolytic Anemia — all drugs for Autoimmune Hemolytic Anemia →
Failure of Two Rounds of Treatment — all drugs for Failure of Two Rounds of Treatment →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

18 and older, any sex, with Autoimmune Hemolytic Anemia or Failure of Two Rounds of Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multicenter, single-arm, pilot study. The aim of this study is to evaluate the efficacy and safety of Linperlisib, the PI3K delta inhibitor for autoimmune hemolytic anemia patients who failed the second line therapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

ChemAP: predicting drug approval with chemical structures before clinical trial phase by leveraging multi-modal embedding space and knowledge distillation.
Cho C, Lee S, Bang D, Piao Y, et al · · 2024 · cited 1× · PMID 39362916 · DOI 10.1038/s41598-024-72868-0
[The treatment strategies of autoimmune hemolytic anemia].
Yue WR, Wu T, Wang XQ. · · 2024 · cited 1× · PMID 39134500 · DOI 10.3760/cma.j.cn121090-20231027-00236

Verify or expand the search:

Other trials of Linperlisib

Trials testing the same drug.

NCT07139353 — Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma · Phase 1, PHASE2 · not yet recruiting
NCT07031115 — Linperlisib in the Treatment of aPRCA · Phase 2 · not yet recruiting
NCT06548347 — A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma · Phase 2, PHASE3 · not yet recruiting
NCT06489808 — Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL · Phase 2 · recruiting
NCT06343935 — A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma · Phase 4 · not yet recruiting

Other recruiting trials for Autoimmune Hemolytic Anemia

Currently open trials in the same condition.

NCT07441525 — UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases · EARLY_PHASE1 · recruiting
NCT07175493 — A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia · Phase 1, PHASE2 · recruiting
NCT06921980 — Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia · recruiting
NCT06733610 — CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy. · Phase 1 · recruiting
NCT06888960 — Safety Study of CC312 in Autoimmune Disease Patients · EARLY_PHASE1 · recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05676697 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 11 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05676697.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing